Current Cancer Drug Targets, Volume 11 - Number 3

Editorial [Hot Topic: Targeting Tumor Uniquitin-Proteasome Pathway with New and Old Drugs (Guest Editor: Q. Ping Dou)]

, 11(3): 236 - 238

Q. Ping Dou

DOI: 10.2174/156800911794519789

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

, 11(3): 239 - 253

D. Chen, M. Frezza, S. Schmitt, J. Kanwar and Q. P. Dou

DOI: 10.2174/156800911794519752

Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

, 11(3): 254 - 284

B. C. Potts, M. X. Albitar, K. C. Anderson, S. Baritaki, C. Berkers, B. Bonavida, J. Chandra, D. Chauhan, J. C. Cusack, W. Fenical, I. M. Ghobrial, M. Groll, P. R. Jensen, K. S. Lam, G. K. Lloyd, W. McBride, D. J. McConkey, C. P. Miller, S. T.C. Neuteboom, Y. Oki, H. Ovaa, F. Pajonk, P. G. Richardson, A. M. Roccaro, C. M. Sloss, M. A. Spear, E. Valashi, A. Younes and M. A. Palladino

DOI: 10.2174/156800911794519716

Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)

, 11(3): 285 - 295

D. J. Kuhn, R. Z. Orlowski and C. C. Bjorklund

DOI: 10.2174/156800911794519725

Green Tea Polyphenols as Proteasome Inhibitors: Implication in Chemoprevention

, 11(3): 296 - 306

H. Yang, K. Landis-Piwowar, T. H. Chan and Q. P. Dou

DOI: 10.2174/156800911794519743

Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment

, 11(3): 307 - 324

V. Cecarini, M. Cuccioloni, M. Mozzicafreddo, L. Bonfili, M. Angeletti and A. M. Eleuteri

DOI: 10.2174/156800911794519815

Clioquinol – A Novel Copper-Dependent and Independent Proteasome Inhibitor

, 11(3): 325 - 331

A. D. Schimmer

DOI: 10.2174/156800911794519770

Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome

, 11(3): 332 - 337

B. Cvek

DOI: 10.2174/156800911794519806

Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies

, 11(3): 338 - 346

F. R. Kona, D. Buac and A. M. Burger

DOI: 10.2174/156800911794519798

SCF E3 Ubiquitin Ligases as Anticancer Targets

, 11(3): 347 - 356

L. Jia and Y. Sun

DOI: 10.2174/156800911794519734

Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies

, 11(3): 357 - 379

S. Meschini, M. Condello, P. Lista and G. Arancia

DOI: 10.2174/156800911794519707

Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide

, 11(3): 380 - 392

R. Mathur, S. Chandna, P. N. Kapoor and B. S. Dwarakanath

DOI: 10.2174/156800911794519761

Webmaster Contact:
Copyright © 2018 Bentham Science